In a nutshell This study aimed to measure the effectiveness of bendamustine and rituximab as salvage treatment in patients with chronic lymphocytic leukemia. This study concluded that bendamustine and rituximab are as effective as ibrutinib as salvage treatment in these patients. Some background The standard treatment for chronic lymphocytic...
Read More
In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with mantle cell lymphoma (MCL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of care for...
Read More
In a nutshell This study aimed to investigate if dasatinib could be successfully discontinued in chronic myeloid leukemia patients who were receiving it as a second line treatment after a year of deep molecular response. This study concluded that it was possible to discontinue dasatinib use in this group of patients. Some background Imatinib...
Read More
In a nutshell This study investigated the outcomes of primary refractory or relapsed Hodgkin’s lymphoma (HL) patients who received GBM (gemcitabine, busulfan, melphalan) or BEAM (carmustine, etoposide, cytarabine, melphalan) chemotherapy before autoSCT (autologous stem cell transplantation). This study concluded that GBM improved patient outcomes...
Read More
In a nutshell This study investigated the effectiveness and safety of short 15-minute panitumumab (Vectibix) injections. Researchers suggested that these injections were well tolerated with manageable side effects. Some background Panitumumab is a therapy that targets the EFGR receptor on cancer cells. This blocks cell growth which results in cell...
Read More
In a nutshell This study aimed to investigate the effectiveness and safety of ponatinib (Iclusig) for patients with chronic phase chronic myelogenous leukemia. This study concluded that ponatinib is safe and effective in this group of patients. Some background The Philadelphia chromosome (BCR-ABL1) is found in almost all patients with chronic...
Read More
In a nutshell This study compared the outcomes of different salvage treatments in patients with aggressive B-cell non-Hodgkin lymphoma with PET-positive disease (remaining cancer cells) after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. This study concluded that B-cell NHL patients with PET-positive...
Read MoreIn a nutshell This study aimed to compare myeloablative transplant and a sequential approach treatment in patients with relapsed or refractory acute myeloid leukemia. This study concluded that both treatments had similar outcomes for these patients. Some background Allogeneic hematopoietic stem cell transplantation (HSCT) is the only...
Read More
In a nutshell This phase 3 trial aims to determine the effectiveness of Iomab-B before an hematopoietic stem cell transplantation compared to conventional treatment. The outcome to be measured is remission (no disease) and survival. The details Acute myeloid leukemia is a type of bone marrow cancer. Iomab-B is a drug in development for...
Read More
In a nutshell This phase 1 and 2 trial aims to determine the effectiveness and optimal dose of Axitinib and Bosutinib in patients with chronic myeloid leukemia. The outcome to be measured is the response to treatment based on genetic analysis and blood cell count, and the side effects. The study is located in Houston, Texas, United States. The...
Read MoreIn a nutshell This study examined the effectiveness of lenalidomide (Revlimid) in patients with mantle cell lymphoma (MCL) already treated with ibrutinib (Imbruvica). The authors concluded that lenalidomide was effective following ibrutinib. Some background There is no standard-of-care treatment for patients with relapsed or refractory (did not...
Read More
In a nutshell This study aimed to determine which patients benefited most from abiraterone acetate (Zytiga) and prednisone (Deltasone). This study found that overall survival was increased for all patient groups that received this combination. Some background A main treatment option for prostate cancer is androgen deprivation...
Read More
